Week 96 Results of Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV Treatment in People With Substance Use Disorders
At W96, the proportion of PWH/SUD achieving VS with B/F/TAF decreased to 44%, along with an adherence decrease of 18%, with no evidence of treatment-emergent HIV drug resistance occurring.
Authors
- Nada Fadul (ORCID: https://orcid.org/0000-0001-5022-9063)
- Joshua P Havens (ORCID: https://orcid.org/0000-0001-9894-615X)
- Susan Swindells (ORCID: https://orcid.org/0000-0001-5826-6037)
- Elizabeth Lyden
- Sara Hurtado Bares (ORCID: https://orcid.org/0000-0002-2130-2505)
Institutions
- Nebraska Medical Center (US)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-12-20
- DOI
- https://doi.org/10.1093/ofid/ofae737
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- OPEC Fund for International Development
- Gilead Sciences
- University of Nebraska Medical Center
- ViiV Healthcare